Simons MP, Moore JM, Kemp TJ, Griffith TS. Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils. Infect Immun. 2007 Mar;75(3):1265-71. Epub 2006 Dec 28. PubMed PMID: 17194806; PubMed Central PMCID:PMC1828584.

Kemp TJ, Ludwig AT, Earel JK, Moore JM, Vanoosten RL, Moses B, Leidal K, Nauseef WM, Griffith TS. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood. 2005 Nov 15;106(10):3474-82. Epub 2005 Jul 21. PubMed PMID: 16037389; PubMed Central PMCID: PMC1895062.

Kemp TJ, Moore JM, Griffith TS. Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation. J Immunol. 2004 Jul 15;173(2):892-9. PubMed PMID: 15240676.

Kemp TJ, Kim JS, Crist SA, Griffith TS. Induction of necrotic tumor cell death by TRAIL/Apo 2L. Apoptosis. 2003 Dec;8(6):587-99. PubMed PMID: 14739604.

Kemp TJ, Elzey BD, Griffith TS. Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J Immunol. 2003 Jul 1;171(1):212-8. PubMed PMID: 12817000.

Griffith TS, Kemp TJ. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. Cancer Chemother Pharmacol. 2003 Sep;52(3):175-84. Epub 2003 Jun 14. PubMed PMID:12811515.